Pure tone audiometric findings in patients on second‑line treatment for multidrug‑resistant tuberculosis
Main Article Content
Abstract
Background: The need for second-line antitubercular medication has been on the increase due to the emergence of multidrug-resistant strain tuberculosis (MDR-TB) in our environment.
Aim: This study was to assess the effect of second-line antitubercular medication on hearing in patients with MDR-TB.
Patients and Methods: This is a prospective study of all the patients admitted to the MDR-TB center of the University of Port Harcourt Teaching Hospital between January and May 2013. All patients had pure tone audiometry done before and 3 months after commencement of second-line antitubercular medications. The second-line regimen used includes kanamycin, levofloxacin, cycloserine, pyrazinamide, and pyridoxine.
Results: The study had a total of 28 patients. There were 14 males and 14 females. The age range was between 18 and 68 years. Different degrees of high-frequency sensorineural hearing loss(SNHL) were seen in 14 patients after 3 months’ therapy. There were 13 bilateral and 1 unilateral hearing impairment, 2 patients had profound SNHL. However, a good number had involvement of the speech frequencies.
Conclusion: Second-line antitubercular medication appears to have a tremendous effect on hearing. This raises a public health issue since there is a growing increase in MDR-TB in our environment.
Downloads
Article Details
The journal grants the right to make small numbers of printed copies for their personal non-commercial use under Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported License.
References
1. HarriesAD, Dye C. Tuberculosis. Ann Trop Med Parasitol 2006;100:415‑31.
2. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: World Health Organization; 2006.
3. World Health Organization. Global tuberculosis control: WHO Report 2011. WHO/HTM/TB/2011.16. Geneva: WHO; 2011.
4. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis – Emergency update. WHO/HTM/TB/2008.402. Geneva: WHO; 2008.
5. Espinal MA. The global situation of MDR‑TB. Tuberculosis (Edinb) 2003;83:44‑51.
6. World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis: 2011 update. WHO/HTM/TB/2011.4. Geneva: World Health Organization; 2011.
7. Sharma SK, Mohan A. Multidrug‑resistant tuberculosis: A menace that threatens to destabilize tuberculosis control. Chest 2006;130:261‑72.
8. Drobniewski FA, Balabanova YM. The diagnosis and management of multiple‑drug‑resistant‑tuberculosis at the beginning of the new millenium. Int J Infect Dis 2002;6 Suppl 1:S21‑31.
9. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long‑term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6:622‑7.
10. Ackerman BH, Bailie GR, Zaske DE. Aminoglycoside therapy. Improving patient response and safety. Postgrad Med 1984;75:177‑86.
11. Seddon JA, Godfrey‑Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug‑resistant
tuberculosis. Eur Respir J 2012;40:1277‑86.
12. Selimoglu E. Aminoglycoside‑induced ototoxicity. Curr Pharm Des 2007;13:119‑26.
13. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008;249:91‑6.
14. Duggal P, Sarkar M. Audiologic monitoring of multi‑drug resistant tuberculosis patients on aminoglycoside treatment with long term follow‑up. BMC Ear Nose Throat Disord 2007;7:5.
15. Campbell KC. Audiologic monitoring for toxicity. In: Roland P, Rutka J, editors. Ototoxicity. New York: BC Decker Publishers; 2004. p. 153‑60.
16. American Speech‑Language‑Hearing Association (ASHA). Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994;36 Suppl 12:11‑9.
17. Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, et al. Prevalence of multidrug‑resistant tuberculosis among category 11
pulmonary tuberculosis patients. Indian J Med Res 2011;133:312‑5.
18. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug‑resistant tuberculosis: Results from the DOTS‑Plus initiative. Int J Tuberc Lung Dis 2004;8:1382‑4.
19. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of serious adverse effects in patients receiving community‑based therapy for multidrug‑resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:648‑55.
20. Sturdy A, Goodman A, José RJ, Loyse A, O’Donoghue M, Kon OM, et al. Multidrug‑resistant tuberculosis (MDR‑TB) treatment in the UK: A
study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815‑20.
21. Sagwa E, Mantel‑Teeuwisse AK, Ruswa N, Musasa JP, Pal S, Dhliwayo P, et al. The burden of adverse events during treatment of drug‑resistant
tuberculosis in Namibia. South Med Rev 2012;5:6‑13.
22. Tahaoglu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, et al. The treatment of multidrug‑resistant tuberculosis in Turkey. N Engl J Med 2001;345:170‑4.
23. Brummett RE, Fox KE. Aminoglycoside‑induced hearing loss in humans. Antimicrob Agents Chemother 1989;33:797‑800.
24. Matz GJ. Aminoglycoside cochlear ototoxicity. Otolaryngol Clin North Am 1993;26:705‑12.
25. Wang S, Bian Q, Liu Z, Feng Y, Lian N, Chen H, et al. Capability of serum to convert streptomycin to cytotoxin in patients with aminoglycoside‑induced hearing loss. Hear Res 1999;137:1‑7.
26. Idigbe EO, Sofola T, Akinosho R, Onwujekwe D, Odiah F, Okoye R. Initial drug resistance tuberculosis amongst HIV seropositive and seronegative prison inmates in Lagos, Nigeria. Int Conf AIDS 1998;12:137.
27. Lawson L, Yassin MA, Thacher TD, Olatunji OO, Lawson JO, Akingbogun TI, et al. Clinical presentation of adults with pulmonary tuberculosis with and without HIV infection in Nigeria. Scand J Infect Dis 2008;40:30‑5.
28. United States Embassy in Nigeria. Nigeria Tuberculosis Fact Sheet: US Embassy in Nigeria; 2012. Available from: http://www.nigeria.usembassy.gov. [Last accessed on 2015 May 15].